First Results with Erdafitinib-Releasing Intravesical Delivery System (TAR-210) Show Early Evidence of Positive Clinical Activity in Patients with Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery system  Phase 1 results show a manageable safety profile with limited systemic toxicity, and early complete responses in patients with high-risk and intermediate-risk NMIBC MADRID, Oct. 22, 2023 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & […]

Related Keywords

Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Vilaseca ,Madrid ,Obrian Kenney ,Jeffrey Infante ,Johnson ,European Society For Medical Oncology ,Companies Of Johnson ,Janssen Biotech Inc ,Janssen Pharmaceutical Companies Of Johnson ,Translational Research ,Exchange Commission ,Oncology Early Clinical Development ,None Of Janssen Research Development ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Late Breaking Mini Oral Presentation Session ,European Society ,Medical Oncology ,Antoni Vilaseca ,Global Head ,Janssen Research ,Bacillus Calmette Gu ,Pharmaceutical Companies ,Pulmonary Hypertension ,Janssen Biotech ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Efficacy Results ,Intravesical Delivery System ,Muscle Invasive Bladder Cancer ,With Select ,Unresponsive Non Muscle Invasive Bladder Cancer ,Current Treatment Landscape ,Novel Emerging Molecular ,Intj Mol ,